Pujiang Prostate Cancer Academic Conference | Prof. Fangning Wan: Innovations in Local Therapy, Advances in Systemic Treatment, and Clinical Applications of Cryotherapy for Prostate Cancer

Pujiang Prostate Cancer Academic Conference | Prof. Fangning Wan: Innovations in Local Therapy, Advances in Systemic Treatment, and Clinical Applications of Cryotherapy for Prostate Cancer

The 2026 Pujiang Prostate Cancer Academic Conference was held in Shanghai from June 26–27, 2026. As treatment strategies for prostate cancer continue to evolve, local therapy has progressed beyond conventional radical surgery toward robot-assisted precision surgery with greater emphasis on functional preservation. Meanwhile, focal therapies such as cryoablation and irreversible electroporation (IRE) have emerged as promising treatment options for carefully selected patients.
Advances in ADC Therapy for Advanced Urothelial Carcinoma | Prof. Kaiwei Yang Reviews the Evolving First- and Later-Line Treatment Landscape

Advances in ADC Therapy for Advanced Urothelial Carcinoma | Prof. Kaiwei Yang Reviews the Evolving First- and Later-Line Treatment Landscape

The treatment landscape for advanced urothelial carcinoma (UC) has entered a new era. Antibody-drug conjugates (ADCs) targeting Nectin-4, HER2, and Trop-2 have rapidly transformed clinical practice, while ADCs combined with immune checkpoint inhibitors have become the new standard for first-line treatment. At the 2026 CSCO Annual Meeting, Prof. Kaiwei Yang from the Department of Urology, Peking University First Hospital presented a comprehensive overview of the current evidence supporting approved and investigational ADCs. Drawing on the latest 2026 CSCO Guidelines, he systematically reviewed first-line treatment strategies, sequencing after disease progression, breakthroughs in domestically developed ADCs, and the next generation of emerging targets, providing valuable insights into individualized treatment for advanced urothelial carcinoma.
Prof. Benkang Shi: Building Academic Synergy Across the Yellow River Region to Advance High-Quality Development of Urology in Shandong

Prof. Benkang Shi: Building Academic Synergy Across the Yellow River Region to Advance High-Quality Development of Urology in Shandong

The 3rd Yellow River Urology Congress and the 31st Academic Conference on Urology of the Shandong Medical Association were recently held, bringing together leading urologists from across China to discuss the latest advances in the field, innovations in clinical practice, talent development, and regional collaboration.
CUDA 2026 | Prof. Xiaoying Li: From Technological Innovation to MDT Collaboration—Redefining the Landscape of Urologic Oncology

CUDA 2026 | Prof. Xiaoying Li: From Technological Innovation to MDT Collaboration—Redefining the Landscape of Urologic Oncology

The 2026 Annual Meeting of the Chinese Urological Association (CUDA) was held in Zhengzhou from June 11–14, bringing together leading experts in urology and related disciplines under the theme "Unity, Collaboration, Innovation, and Development." The meeting focused on advancing high-quality clinical research, technological innovation, multidisciplinary collaboration (MDT), and regional cooperation, while promoting the continued development of comprehensive care for urologic diseases.
Breaking New Ground in Oligometastatic Kidney Cancer | Prof. Liru He’s Team Reports Sunitinib Plus SBRT Strategy in Cell Reports Medicine

Breaking New Ground in Oligometastatic Kidney Cancer | Prof. Liru He’s Team Reports Sunitinib Plus SBRT Strategy in Cell Reports Medicine

The treatment landscape for renal cell carcinoma (RCC), one of the most common malignancies of the urinary system, continues to evolve rapidly, with targeted therapy combined with immunotherapy now established as a standard first-line approach for advanced and metastatic disease. However, for patients with oligometastatic RCC, a standardized treatment strategy has yet to be established.
19th CUA Genitourinary Oncology Conference | Professor Baojun Wang: Breaking Through the Bottlenecks in Prostate Cancer Treatment—Balancing Clinical Innovation with Standardized Care

19th CUA Genitourinary Oncology Conference | Professor Baojun Wang: Breaking Through the Bottlenecks in Prostate Cancer Treatment—Balancing Clinical Innovation with Standardized Care

The 19th Chinese Urological Association (CUA) Genitourinary Oncology Conference was held in Beijing on July 3–4, 2026, under the theme "Advancing Frontiers, Standardizing Care, and Driving Collaborative Innovation." The meeting brought together leading experts in urologic oncology from across China to examine the current challenges facing the field and explore future directions for clinical research and patient care.
19th CUA Genitourinary Oncology Conference | Professor Xuesong Li: Advancing the UTUC Subspecialty Through High-Quality Research to Address Key Clinical Challenges

19th CUA Genitourinary Oncology Conference | Professor Xuesong Li: Advancing the UTUC Subspecialty Through High-Quality Research to Address Key Clinical Challenges

The 19th Chinese Urological Association (CUA) Genitourinary Oncology Conference was held in Beijing on July 3–4, 2026, bringing together leading experts from across China under the theme "Advancing Frontiers, Standardizing Care, and Driving Collaborative Innovation." The meeting provided a platform for discussing new directions in urologic oncology research and clinical practice.
19th CUA Genitourinary Oncology Conference | Professor Kan Gong: Taking a Pragmatic View of AI in Clinical Practice While Building a China-Specific Evidence Base for Urologic Oncology

19th CUA Genitourinary Oncology Conference | Professor Kan Gong: Taking a Pragmatic View of AI in Clinical Practice While Building a China-Specific Evidence Base for Urologic Oncology

The 19th Chinese Urological Association (CUA) Genitourinary Oncology Conference was successfully held in Beijing on July 3–4, 2026. Centered on the theme "Advancing Frontiers, Standardizing Care, and Driving Collaborative Innovation," the meeting featured in-depth discussions on precision oncology, early screening and prevention of prostate cancer, and the development of a robust domestic clinical research ecosystem, highlighting both the latest advances and the key challenges facing urologic oncology in China.
Professor Benlong Yang: Breast Surgery Enters the Era of De-escalation and Individualized Care in Precision Oncology | 2026 CACA Cancer Prevention and Screening Conference

Professor Benlong Yang: Breast Surgery Enters the Era of De-escalation and Individualized Care in Precision Oncology | 2026 CACA Cancer Prevention and Screening Conference

The 2026 CACA Cancer Prevention and Screening Conference recently opened in Hangzhou, bringing together leading oncologists, researchers, and industry experts from across China to discuss advances in cancer prevention, early detection, multidisciplinary collaboration, and translational research. Hosted by the Chinese Anti-Cancer Association (CACA) and its Cancer Prevention and Screening Committee, the meeting aligns with the goals of the Healthy China 2030 initiative by promoting earlier intervention throughout the cancer care continuum.